Document:

Exhibit

Exhibit 10.33

CF INDUSTRIES HOLDINGS, INC.
2014 EQUITY AND INCENTIVE PLAN
PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT
Name of Grantee:  <first_name> <last_name>
Maximum Payout of Performance Restricted Stock Units:  [220% of Target]
Target Payout for Performance Restricted Stock Units: [Amount ]
Grant Date:  <award_date>    
Vesting Date: The Performance Restricted Stock Units will vest on the third anniversary of the Grant Date, subject to the attainment of the performance goals set forth on Exhibit A hereto, but shall be subject to forfeiture or accelerated vesting as described herein.
Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms as defined in the CF Industries Holdings, Inc. 2014 Equity and Incentive Plan (the “Plan”).  Please review this Award Agreement and promptly accept the award online, in Schwab’s Equity Award Center, in order to render the grant effective.
*        *        *        *        *
1.    You have been granted the Performance Restricted Stock Units shown above pursuant to the Plan and subject to the terms and conditions of the Plan and this Award Agreement. Each Performance Restricted Stock Unit represents the right to receive a share of Stock upon the vesting of the Performance Restricted Stock Unit.  
2    From the Grant Date until the Vesting Date, you may not sell, assign, transfer, donate, pledge or otherwise dispose of the Performance Restricted Stock Units (except by will or the laws of descent and distribution). 
3.    The Performance Restricted Stock Units shall vest on the Vesting Date, subject to attainment of the performance goals set forth on Exhibit A hereto and subject to earlier vesting upon a Change in Control (except as limited under Section 5) or as otherwise provided herein.  Except as set forth in Section 5, shares of Stock shall be delivered (provided, that such delivery is otherwise in accordance with federal and state securities laws) with respect to the vested Performance Restricted Stock Units as soon as practicable following the Vesting Date (or the date of your Disability or death, as applicable), but in no event later than March 15 of the calendar year following the calendar year in which the Vesting Date (or the date of your Disability or death, as applicable) occurs.
4.    If your employment with the Company and its Subsidiaries shall terminate for any reason other than due to your death, Disability or Special Retirement (as defined below) prior to the Vesting Date, the Performance Restricted Stock Units shall be forfeited.  In the event of termination of your employment due to your death or Disability, the Performance Restricted Stock Units shall vest as of the date of any such termination, with the number of Restricted Stock Units that become vested to be calculated based on the deemed attainment of the target level of performance set forth on Exhibit A (without any modifications based on the TSR Comparator Group), provided that the number of Performance Restricted Stock Units that shall become vested on any such termination date shall be pro-rated based the number of months you were employed prior to any such termination date, determined by multiplying the number of Restricted Stock Units that become vested based on the deemed attainment of the target level of performance by a fraction, the numerator of which is the number of full months between the Grant Date and the date of your termination due to death or Disability and the denominator of which is 36, the number of months from the Grant Date to the Vesting Date. You shall be entitled to a cash payment equal to the Fair Market Value, determined as of the date of any such termination, of the shares of Stock underlying any Restricted Stock Units that become so vested, with such cash payment to be made within forty-five (45) days of any such termination of employment.  In the event of termination of your employment due to Special Retirement, the Performance Restricted Stock Units shall remain eligible to vest on the Vesting Date subject to attainment of the performance goals set forth on Exhibit A hereto, provided that the number 

of Performance Restricted Stock Units that shall become vested on the Vesting Date shall be pro-rated based the number of months you were employed prior to the date of your termination due to Special Retirement, determined by multiplying the number of Restricted Stock Units that become vested based on the attainment of performance goals set forth on Exhibit A by a fraction, the numerator of which is the number of full months between the Grant Date and the date of your termination due to Special Retirement and the denominator of which is 36, the number of months from the Grant Date to the Vesting Date.
For purposes of this Award Agreement, “Disability” shall have the meaning ascribed to such term in your individual employment, severance or other agreement with the Company or, if you are not party to such an agreement, “Disability” shall mean your inability because of ill health, physical or mental disability, to perform your duties for a period of 180 days in any twelve month period.  For purposes of this Award Agreement, “Special Retirement” shall mean your termination of employment, other than for “Cause,” death or Disability, following the attainment by you of at least age sixty with five (5) years of continuous service with the Company as of the date of such termination of employment, provided that, if you are, at the time of such termination of employment, subject to the reporting requirements of Section 16 of the Exchange Act, you have provided the Company with at least six months prior written notice of your termination of employment and that notice has been accepted by the Committee.  For purposes of this Award Agreement, “Cause” shall have the meaning ascribed to such term in any individual employment, severance or other agreement with the Company to which you are a party or, if you are not party to such an agreement, “Cause” shall mean (i) dishonesty in the performance of your duties, (ii) your malfeasance or misconduct in connection with your duties, or (iii) any act or omission which is injurious to the Company or its Subsidiaries or affiliates, monetarily or otherwise, each as determined by the Committee in its sole discretion.  For purposes of this Award Agreement, “Good Reason” shall mean termination by you of your employment by reason of any of the following (without your express written consent which specifically references this Award Agreement):  (i) the assignment to you of any duties inconsistent with your status as an executive officer of the Company or a substantial adverse alteration in the nature or status of your responsibilities from those in effect immediately prior to the Change in Control; (ii) a reduction by the Company in your annual base salary and annual target bonus, as in effect on the date hereof or as the same may be increased from time to time, by an amount more than 10% in the aggregate; or (iii) the relocation of your principal place of employment to a location more than 35 miles from your principal place of employment immediately prior to the Change in Control or the Company's requiring you to be based anywhere other than such principal place of employment (or permitted relocation thereof) except for required travel on the Company's business to an extent substantially consistent with the business travel obligations as of immediately prior to a Change in Control.  Your continued employment shall not constitute consent to, or a waiver of rights with respect to, any act or failure to act constituting Good Reason hereunder, provided that, in order for Good Reason to exist hereunder, you must provide notice to the Company of the existence of the condition described in clauses (i) through (iii) above within 90 days of the initial existence of the condition (or, if later, within 90 days of your becoming aware of such condition), and the Company must have failed to cure such condition within 30 days of the receipt of such notice. 
For the avoidance of doubt and solely for purposes of this Award Agreement, if you enter into an agreement with the Company to transition directly from an employment relationship into a consulting relationship, you shall not, unless otherwise determined by the Committee, be deemed to have terminated employment upon such transition from an employment relationship into a consulting relationship.  In the event of such a transition, the Performance Restricted Stock Units shall continue to be eligible to vest in accordance with its terms, as if no termination had occurred, for so long as such consulting relationship remains in effect.  The continued existence of the consulting relationship shall be determined by the Committee or its delegate and the continued vesting of the Performance Restricted Stock Units shall not be construed for any other purpose to mean you remain employed with the Company following such transition.
Neither the grant of the Performance Restricted Stock Units, this Award Agreement nor any other action taken pursuant to this Award Agreement shall constitute or be evidence of any agreement or understanding, express or implied, that you have a right to continue to provide services as an officer, director, employee or consultant of the Company for any period of time or at any specific rate of compensation.  
5.    In the event of a Change in Control, the Performance Restricted Stock Units shall vest and be delivered (provided, that such delivery is otherwise in accordance with federal and state securities laws) on the date of such Change in Control, with the number of Performance Restricted Stock Units that become vested to be calculated based on the greater of target and actual attainment of the performance goals set forth on Exhibit A measured as of the date of such Change in Control (with the three-year period for measurement of performance goals shortened and ending on such date).  Notwithstanding the foregoing or anything to the contrary in the Plan or in the Combination Agreement by and among the Company, Darwin Holdings Limited, Beagle Merger Company LLC, OCI N.V. and certain other parties, dated August 6, 2015, as subsequently amended and as may be further amended (the “Combination Agreement”) and notwithstanding that completion of the transactions contemplated under the Combination Agreement (the “Closing”) would constitute a “Change in Control” under the Plan, the Performance Restricted Stock Units shall not vest in whole or in part upon, or in connection with, the Closing.   The Performance Restricted Stock Units will be converted upon the Closing into performance restricted stock units covering shares of the surviving holding 

company (as provided under the Combination Agreement), with the number of Performance Restricted Stock Units subject to this Award adjusted to preserve the value of the Award, and will otherwise be subject to the terms and conditions set forth in this Award Agreement and in the Plan, including the vesting terms; provided, that, in the event your employment is terminated by the Company without Cause (as defined above) or by you for Good Reason (as defined above) prior to the Vesting Date and within 24 months following the Closing, the Performance Restricted Stock Units will vest and be delivered (provided, that such delivery is otherwise in accordance with federal and state securities laws) on the date of such termination of employment, with the number of Performance Restricted Stock Units that become vested to be calculated based on the greater of target and actual attainment of the performance goals set forth on Exhibit A measured as of the date of such employment termination (with the three-year period for measurement of performance goals shortened and ending on such date).

6.    Unless and until a certificate or certificates representing shares of Stock shall have been issued by the Company as a result of the vesting of the Performance Restricted Stock Units, you shall not have any of the rights or privileges of a stockholder of the Company with respect to the shares of Stock subject to the Performance Restricted Stock Units.  

7.     The Performance Restricted Stock Units will carry dividend equivalent rights related to any cash dividend paid by the Company while the Performance Restricted Stock Units are outstanding.  In the event the Company pays a cash dividend on its outstanding shares of Stock following the grant of the Performance Restricted Stock Units, your Performance Restricted Stock Units will accrue dividend equivalents.  Upon vesting of your Performance Restricted Stock Units, you will be paid a cash equivalent of the dividends paid during the performance and vesting periods based on the number of shares of Stock, if any, delivered in the settlement of your Performance Restricted Stock Units.

8.    The Company or a Subsidiary shall withhold all applicable taxes or other amounts required by law from all amounts paid or delivered in respect of the Performance Restricted Stock Units. You may satisfy the withholding obligation by paying the amount of any taxes in cash or shares may be withheld from the shares of Stock otherwise deliverable to satisfy the obligation in full or in part.  If shares are withheld, such shares shall have a Fair Market Value equal to the minimum statutorily required withholding obligation (reduced by the amount of any taxes paid in cash), with such number of withheld shares rounded up to the nearest whole number of shares as necessary to avoid fractional shares and with any excess amount refunded in cash to you.

9.    The intent of you and the Company is that payments and benefits under this Agreement and the Award be exempt from, or comply with, Section 409A of the Internal Revenue Code (the “Code”), and accordingly, to the maximum extent permitted, this Agreement and the Award shall be interpreted and administered to be in accordance therewith. Each payment under this Agreement and the Award shall be construed as a separate identified payment for purposes of Section 409A of the Code, and any payments described in this Agreement and the Award that are due within the “short term deferral period” as defined in Section 409A of the Code shall not be treated as deferred compensation unless applicable law requires otherwise. Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, (i) you shall not be considered to have terminated employment for purposes of this Award Agreement and no payments shall be due to you under this Award Agreement that are payable upon your termination of employment until you would be considered to have incurred a “separation from service” from the Company within the meaning of Section 409A of the Code and (ii) amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Award Agreement and the Award during the six-month period immediately following your separation from service shall instead be paid on the first business day after the date that is six months following your separation from service (or, if earlier, your death).

10.    By accepting this Award Agreement you agree that, upon the request of the Committee (which may choose, in its discretion, whether or not to invoke its rights under this paragraph), you will immediately repay some or all of any amounts paid to you under this Award Agreement.  You will be required to repay amounts paid to you upon the request of the Committee if the performance levels set forth in this Award Agreement are attained (or mistakenly thought to be attained) due to (i) an error or misconduct by you or (ii) any event or circumstance which results in a restatement of the financial statements of CF Industries Holdings, Inc. which restatement occurs on or prior to April 1 of the year following  the year in which you are paid any amounts under the Award Agreement (without giving effect to any deferral of payment).  The maximum amount of the repayment would be the difference between (i) the payment actually paid to you under this Award Agreement and (ii) the payment that would have been made to you under this Award Agreement absent such error or misconduct or after giving effect to such restatement.  You also agree that, in the event that you fail to make such reimbursement promptly, the Company may withhold from your future compensation the amount which you failed to repay, in satisfaction of such repayment obligation.  To the extent possible, the amount of your repayment will be netted against any income earned by you in that year.  Any repayment obligation will be communicated to you by the Committee and the right of the Committee to demand repayment and your obligation to make such repayment are each subject to compliance with law. 

11.    The Plan is incorporated herein by reference.  The Plan and this Award Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of you and the Company with respect to the subject matter hereof, and may not be modified except by means of a writing signed by you and the Company.  If there is a conflict between the terms and conditions of the Plan and the terms and conditions of this Award Agreement, the terms and conditions of the Plan shall govern. This Award Agreement is governed by the internal substantive laws, but not the choice of law rules, of the State of Delaware.
By your signature and the signature of the Company’s representative below, you and the Company agree this Award is granted under and governed by the terms and conditions of the Plan, the terms of which are incorporated herein, and this Award Agreement.  You have reviewed the Plan and this Award Agreement in their entirety, have had an opportunity to obtain the advice of counsel prior to executing this Award Agreement and fully understand all provisions of the Plan and Award Agreement.  You hereby agree to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan and Award Agreement.  You further agree to notify the Company upon any change in your residential address shown below.
	
			
	GRANTEE
	 
	CF INDUSTRIES HOLDINGS, INC.

	 
	 
	 

	<first_name> <last_name> 
	 
	By:  Wendy S. Jablow

	<address_1>
<city>, <state> <zip> 
	 
	Title:  Sr. Vice President, Human Resources

 

Exhibit A
Performance Vesting Criteria 
The number of Performance Restricted Stock Units (also referred to as “PSUs”) that vest will be determined by a two-step process.

		
	1.
	The initial performance measurement shall be based on the Total Shareholder Return (or “TSR”) with respect to a share of Stock as compared to the Total Shareholder Return of the S&P 500, in each case over the three year period commencing on January 1 of the year in which the Grant Date occurs (the “Performance Period”). The companies constituting the Standard & Poor’s 500 Index (the “Index”) as of the beginning of the Performance Period will be compared with the companies in the Index at the end of such Performance Period and only those companies that are in the Index at both times will be included in the S&P 500 for purposes of the comparison. The chart below shows the portion of the total number of Performance Restricted Stock Units that will vest based on the Total Shareholder Return measurement:

	
						
	Level
	 
	Company TSR Relative to TSR of S&P 500
	 
	PSUs to vest (% of target payout for Award)
	

	 
	 
	 
	 
	 

	Threshold
	 
	25th Percentile
	 
	50
	%

	Target
	 
	50th Percentile
	 
	100
	%

	Maximum
	 
	75th Percentile or better
	 
	200
	%

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

No Performance Restricted Stock Units will be paid out in the event of performance below the Threshold Level. Payouts with respect to performance in between the performance levels set forth in the chart above shall be determined by linear interpolation.

For purposes of the preceding calculation and the TSR Comparator Group calculation below, Total Shareholder Return for the Company and each member of the TSR Comparator Group identified below shall mean:

(stock price at the end of the Performance Period - stock price at the beginning
		
	 
	of the Performance Period) + Amount of Dividends Paid      stock price at the beginning of the Performance Period

For purposes of the preceding calculation (i) the stock price shall be calculated as the average closing stock price of the stock on its primary US stock exchange (or, if not traded on a US exchange, its primary foreign securities exchange, with respect to foreign members of the TSR Comparator Group) for the thirty (30) trading days immediately preceding the applicable date of determination and (ii) the “Amount of Dividends Paid” shall mean the sum of all dividends paid during the Performance Period. Stock prices and dividends paid denominated in non-U.S. dollars for any member of the TSR Comparator Group shall be converted to U.S. dollars using the currency exchange rates in effect on each relevant trading day and/or date of dividend payment, as applicable. Such calculation shall also be adjusted as deemed appropriate by the Committee to reflect any stock split, reverse stock split or other similar corporate transaction.

		
	2.
	The number of Performance Restricted Stock Units which vest based on the initial TSR calculation shall then be adjusted based upon the Company’s TSR, ranked against the TSR achieved by the members of the TSR Comparator Group identified below, in accordance with the following:

	
			
	Company Ranking
	 
	Percentage Increase or Decrease to Number of PSUs

	 
	 
	 

	1st
	 
	+20%

	2nd or 3rd
	 
	+10%

	4th or 5th
	 
	No modification

	6th or 7th
	 
	-10%

	8th
	 
	-20%

	 
	 
	 

	 
	 
	 

	 
	 
	 

In the event that this adjustment results in a payment that would be less than the Threshold vesting level in the initial calculation, no Performance Restricted Stock Units shall vest. The final number of Performance Restricted Stock Units to vest based on the adjusted calculation shall be rounded down to the nearest whole share, and a cash payment shall be made in lieu of any fractional shares, with any such cash payment to be made at such time that the corresponding shares of Stock, if any, are delivered in settlement of your Performance Restricted Stock Units, with the amount of such cash payment to be based on the Fair Market Value of the shares underlying the Performance Restricted Stock Units on such date.

The TSR Comparator Group is Agrium Inc., CVR Partners, LP, Incitec Pivot Ltd., LSB Industries, Inc., The Mosaic Company, Potash Corporation of Saskatchewan Inc., Yara International ASA, and CF Industries Holdings, Inc. If a company (or substantially all of its assets) in the TSR Comparator Group is acquired or undergoes a spin-off or similar corporate transaction, such company’s TSR will be indexed to the rest of the companies in the TSR Comparator Group from the effective date of any such transaction until the end of the three-year performance period. If a company in the TSR Comparator Group files for bankruptcy, such company will automatically move to the bottom of the TSR Comparator Group.Exhibit 4.2

 

WARRANT AGREEMENT

 

This Warrant Agreement
made as of [___________], 2016, is between BioLight Life Sciences Ltd., an Israeli company, with offices at Kiryat Atidim Building
3, 5th Floor, Tel Aviv 6158101, Israel (the “Company”), and VStock Transfer, LLC, with offices at
18 Lafayette Place, Woodmere, New York 11598 (the “Warrant Agent”).

 

WHEREAS, the Company
has determined to issue and deliver up to [_________] warrants (the “Warrants”) to investors, each Warrant evidencing
the right of the holder thereof to purchase one ordinary share, NIS 2.5 par value per share (the “Ordinary Shares”),
for $[___] of the Company, subject to adjustment as described herein.

 

WHEREAS, the Company
desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance,
registration, transfer, exchange, redemption and exercise of the Warrants;

 

WHEREAS, the Company
desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the
respective rights, limitation of rights and immunities of the Company, the Warrant Agent and the holders of the Warrants; and

 

WHEREAS, all acts and
things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned
by or on behalf of the Warrant Agent, as provided herein, the legally valid and binding obligations of the Company, and to authorize
the execution and delivery of this Warrant Agreement.

 

NOW, THEREFORE, in
consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1.           Appointment
of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this
Agreement.

 

2.           Warrants.

 

2.1           Form
of Warrant. Each Warrant shall be (a) issued in registered form only, (b) in substantially the form of Exhibit A
attached hereto, the provisions of which are incorporated herein, (c) signed by, or bear the facsimile or electronic
signature of, any two of the Chairman of the Board, the Chief Executive Officer, and the Chief Financial Officer of
the Company, and (d) signed by the Warrant Agent. In the event  that a person whose facsimile signature has been placed upon
any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued,
it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.

 

2.2           Effect
of Countersignature. Unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant shall be invalid
and of no effect and may not be exercised by the holder thereof. Warrant certificates shall be dated the date of countersignature
by the Warrant Agent.

 

     

     

    

  

2.3         Registration.

 

2.3.1           Warrant
Register. The Warrant Agent shall maintain books (“Warrant Register”), for the registration of the original
issuance and transfers of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the
Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered
to the Warrant Agent by the Company.

 

2.3.2           Registered
Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the person in whose name such Warrant shall be registered upon the Warrant Register (“Registered Holder”),
as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other
writing on the warrant certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise
thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

3.           Terms
and Exercise of Warrants.

 

3.1          Exercise
Price. Each Warrant shall entitle the Holder, subject to the provisions of the applicable Warrant Certificate and of this Warrant
Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of US$___ per Ordinary Share,
subject to the subsequent adjustments provided in Section 4 hereof. The term “Exercise Price” as used in this
Warrant Agreement refers to the price per share at which Ordinary Shares may be purchased at the time a Warrant is exercised. 

 

3.2          Duration
of Warrants. A Warrant may be exercised only during the period (“Exercise Period”) commencing on the date
of issuance. For purposes of this Warrant Agreement, the “Expiration Date” shall have the meaning set forth
in the Warrant Certificate. Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder
and all rights in respect thereof under this Agreement shall cease at the close of business on the Expiration Date. 

 

3.3          Exercise
of Warrants.

 

3.3.1           Payment.
Subject to the provisions of the Warrant and this Agreement, a Warrant, when countersigned by the Warrant Agent, may be exercised
by the Registered Holder thereof by (i) submitting a duly executed exercise notice in the form included in Exhibit B, to
the office of the Warrant Agent [____________] which may be done by fax or email delivery, and (ii) by paying to the Company in
full the Exercise Price for each whole Ordinary Share as to which the Warrant is exercised, in lawful money of the United States,
by wire transfer or in good certified check or good bank draft payable to the order of the Company.  In no event shall
the Registered Holder of any Warrant be entitled to “net cash settle” the Warrant. The Registered Holder shall not
be required to deliver the original Warrant being exercised in order to effect an exercise hereunder.  

 

    	 	2	 

     

    

  

***Checks should be payable
to BioLight Life Sciences Ltd. Notice of cash exercise should be made by e-mail (not fax) to [__________]. Originals
need to be mailed to BioLight Life Sciences Ltd., Attention: [____________]. Wired funds for exercise should be
wired to:

 

[_________________]

 

3.3.2           Issuance
of Ordinary Shares. Assuming the exercise notice has been delivered and funds to pay
in full the Exercise Price are paid, each in accordance with Section 3.3.1,
then on or before the third trading day following the date upon which (1) the Warrant Agent has received an exercise notice for a Warrant and (2) the Company has received the funds in full,
the Company shall cause its transfer agent to (i) provided that the transfer agent is participating in The Depository Trust Company
(“DTC”) Fast Automated Securities Transfer Program, credit such aggregate number of Ordinary Shares to which
the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through
its Deposit/Withdrawal at Custodian System, or (ii) if the transfer agent is not participating in the DTC Fast Automated Securities
Transfer Program, issue and deliver to the Holder, or at the Holder’s instruction pursuant to the delivered exercise notice,
the Holder’s agent or designee, in each case pursuant to this clause (ii), sent by reputable overnight courier to the address
specified in the applicable exercise notice, a certificate, registered in the Company’s share register in the name of the
Holder or its designee (as indicated in the applicable exercise notice), for the number of Ordinary Shares to which the Holder
is entitled pursuant to such exercise. 

 

3.3.3           Valid Issuance. All Ordinary Shares issued upon the proper exercise or surrender
of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.

 

3.3.4           Date
of Issuance. Each person or entity in whose name any such certificate for Ordinary Shares is issued shall, for all purposes,
be deemed to have become the holder of record of such shares on the date on which the Warrant was surrendered and payment of the
Exercise Price was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and
payment is a date when the share transfer books of the Company are closed, such person shall be deemed to have become the holder
of such shares at the close of business on the next succeeding date on which the share transfer books are open.

 

    	 	3	 

     

    

  

3.4           Beneficial
Ownership Limitation on Exercises. The Company shall not affect the exercise of any portion of a Warrant, and the Registered
Holder of such Warrant shall not have the right to exercise any portion of such Warrant, to the extent that after giving effect
to such exercise, the Registered Holder (together with the Registered Holder’s affiliates, and any persons acting as a group
together with the Registered Holder or any Registered Holder’s affiliates) would beneficially own in excess of 4.99% (the
“Maximum Percentage”) of the Ordinary Shares outstanding immediately after giving effect to such exercise, provided, however,
that the foregoing limitation on exercise shall not apply to any Registered Holder who, together with such Registered Holder’s
affiliates, and any persons acting as a group together with such Registered Holder and such Registered Holder’s affiliates,
owns in excess of the Maximum Percentage immediately prior to the closing of the Offering.  For purposes of the foregoing
sentence, the aggregate number of Ordinary Shares beneficially owned by such Registered Holder and its affiliates shall include
the number of Ordinary Shares issuable upon exercise of a Warrant with respect to which the determination of such sentence is being
made, but shall exclude Ordinary Shares which would be issuable upon (i) exercise of the remaining, unexercised portion of such
Warrant beneficially owned by the Registered Holder and its affiliates and (ii) exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company beneficially owned by the Registered Holder and its affiliates (including, without
limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Registered Holder or any of its affiliates.  Except
as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  To the
extent that the limitation contained in this Section 3.4 applies, the Registered Holder’s submission of an Election to Purchase
shall be deemed to be the Registered Holder’s determination of whether a Warrant is exercisable (in relation to any other
securities owned by the Registered Holder together with any affiliates) and of which portion of a Warrant is exercisable, in each
case subject to the Maximum Percentage, and the Company shall have no obligation to verify or confirm the accuracy of such determination.  In
addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder.  For purposes of the Warrants, in determining
the number of outstanding Ordinary Shares, the Registered Holder may rely on the number of outstanding Ordinary Shares as reflected
in the most recent of (1) the Company’s most recent Form 20-F, Form 6-K or other public filing with the Commission, as the
case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or its transfer agent
setting forth the number of Ordinary Shares outstanding.  For any reason at any time, upon the written or oral request
of the Registered Holder, the Company shall within three (3) trading days confirm to the Registered Holder the number of Ordinary
Shares then outstanding.  In any case, the number of outstanding Ordinary Shares shall be determined after giving effect
to the conversion or exercise of securities of the Company, including any Warrant, by the Registered Holder and its affiliates
since the date as of which such number of outstanding Ordinary Shares was reported.  By written notice to the Company,
the Registered Holder may from time to time increase or decrease the Maximum Percentage to any other percentage of the number of
Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary Shares upon exercise of a Warrant and the
provisions of this Section 3.4 shall continue to apply; provided that (i) any such increase will not be effective until the sixty-first
(61st) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to that Registered
Holder.  For purposes of clarity, the Ordinary Shares underlying any Warrant in excess of the Maximum Percentage for
a Registered Holder shall not be deemed to be beneficially owned by that Registered Holder for any purpose including for purposes
of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.  The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 3.4 to the extent necessary to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation.

 

    	 	4	 

     

    

  

4.           Adjustments.

 

4.1          Share
Dividends

 

4.1.1           Split-Ups. 
If after the date hereof, and subject to the provisions of Section 4.5 below, the number of outstanding Ordinary Shares is
increased by a share dividend payable in Ordinary Shares, or by a split-up of Ordinary Shares or other similar event, then, on
the effective date of such share dividend, split-up or similar event, the number of Ordinary Shares issuable on exercise of each
Warrant shall be increased in proportion to such increase in the outstanding Ordinary Shares and the Exercise Price shall be proportionally
decreased such that the aggregate Exercise Price, after such adjustments, remains the same for each Warrant.

 

4.1.2           Dividends
and Other Distributions. If the Company shall declare or make any dividend or other distribution of its assets (or rights to
acquire its assets) to holders of Ordinary Shares, by way of return of capital or otherwise (including, without limitation, any
distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction), except to the extent an adjustment was already made pursuant
to Section 4.1.1 or 4.2 (a “Distribution”), at any time after the issuance of a Warrant, then, in each such
case, the Company shall reserve and put aside the maximum Distribution amount the Registered Holder would have been entitled to
receive if the Registered Holder had held the number Ordinary Shares acquirable upon complete exercise of such Warrant immediately
before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record
holders of Ordinary Shares are to be determined for the participation in such Distribution. Upon exercise of a Warrant, in whole
or in part, the Company shall, contemporaneously with the delivery of the Ordinary Shares, distribute to the Registered Holder
a pro rata portion of such Distribution based on the portion of the Warrant that has been exercised (provided, however,
to the extent that the Registered Holder’s right to participate in any such Distributions would result in the Registered
Holder exceeding the Maximum Percentage, then the Registered Holder shall not be entitled to participate in such Distribution at
such time and to such extent (or the beneficial ownership of any such Ordinary Shares as a result of such Distribution to such
extent) and such Distribution to such extent shall be held in abeyance for the benefit of the Registered Holder until such time,
if ever, as its right thereto would not result in the Registered Holder exceeding the Maximum Percentage, at which time or times
the Registered Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or
on any subsequent Distribution to be held similarly in abeyance) to the same extent as if there had been no such limitation).

 

    	 	5	 

     

    

  

4.2           Aggregation
of Shares. If after the date hereof, and subject to the provisions of Section 4.4
hereof, the number of outstanding Ordinary Shares is decreased by a consolidation, combination, reverse share split or reclassification
of Ordinary Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split,
reclassification or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall be decreased in proportion
to such decrease in outstanding Ordinary Shares and the Exercise Price shall be proportionally increased such that the aggregate
Exercise Price, after such adjustments, remains the same for each Warrant.

 

4.3           Purchase
Rights. If at any time the Company grants, issues or sells any options, convertible securities
or rights to purchase shares, warrants, securities or other property pro rata to the record holders of Ordinary Shares (the “Purchase
Rights”), then the Registered Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights which the Registered Holder could have acquired if the Registered Holder had held the number of Ordinary
Shares acquirable upon complete exercise of a Warrant immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that
the Registered Holder’s right to participate in any such Purchase Right would result in the Registered Holder exceeding the
Maximum Percentage, then the Registered Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Registered Holder until such time, if ever, as its right thereto would not result in the Registered
Holder exceeding the Maximum Percentage, at which time or times the Registered Holder shall be granted such right (and any Purchase
Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance)
to the same extent as if there had been no such limitation).

 

    	 	6	 

     

    

  

4.4           Fundamental
Transactions. If, at any time while the Warrants are outstanding, (i) the Company,
directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into
another person, in which the Company is not the surviving entity or the shareholders of the Company immediately prior to such
merger or consolidation do not own, directly or indirectly, a majority of the outstanding voting securities of the
surviving entity, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)
any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is
completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are
effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or
combination of Ordinary Shares covered by Section 4.1 above), or (v) the Company, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another person or group of persons
whereby such other person or group acquires more than 50% of the outstanding Ordinary Shares (not including any Ordinary
Shares held by the other person or other persons making or party to, or associated or affiliated with the other persons
making or party to, such stock or share purchase agreement or other business combination) (each, a
“Fundamental Transaction”), then, upon any subsequent exercise of a Warrant, the Registered Holder of such
Warrant shall be entitled to receive, for each Ordinary Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction (without regard to any limitation in Section 3.4 on the exercise of
the Warrants), the number of Ordinary Shares of the successor or acquiring corporation or of the Company, if it is the
surviving corporation, and any additional consideration (the “Alternate Consideration”) which, in all
cases, was received as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares for which a
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 3.4 on
the exercise of the Warrants). If holders of Ordinary Shares are given any choice as to the securities, cash or property to
be received in a Fundamental Transaction, then each Registered Holder shall be given the same choice as to the
Alternate Consideration. Notwithstanding anything to the contrary, (a) if the holders of Ordinary Shares received, as a
result of such Fundamental Transaction, a consideration or Alternate Consideration (whether from the Company or from any
other person, and whether such consideration or Alternate Consideration is comprised of cash, securities or other property)
(such consideration attributed to one Ordinary Share: the "Fundamental Transaction Consideration Per Ordinary
Share") with respect to some but not all of their Ordinary Shares (including in the event that they have tendered
only some of the Ordinary Shares which such shareholders have initially requested to tender) then, upon any subsequent
exercise of a Warrant, the Registered Holder of such Warrant shall be entitled to receive such consideration on a pro-rata
basis, based on the number of Ordinary Shares underlying its Warrant; and (b) in the event that the Fundamental Transaction
Consideration Per Ordinary Share paid as a result of such Fundamental Transaction is paid by the Successor Entity (as defined
below) or by any other person other than the Company, then such Successor Entity or the other person shall assume and be
responsible to pay the Fundamental Transaction Consideration Per Ordinary Share upon any subsequent exercise of a
Warrant.  The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the
survivor (the “Successor Entity”) to assume in writing all obligations of the Company under each Warrant
in accordance with the provisions of this Section 4.4 pursuant to agreements in form and substance reasonably satisfactory
to the Registered Holders and approved by the Registered Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of each Registered Holder, deliver to such Registered Holder in exchange for
such Registered Holder’s Warrant a written instrument substantially similar in form and substance to such
Registered Holder’s Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable upon exercise of such
Warrant (without regard to the limitations on exercise set forth in Section 3.4) prior to such Fundamental Transaction, and
with an exercise price which applies the Exercise Price hereunder to such shares of capital stock (but taking into account
the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value
of such Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of
such Fundamental Transaction, the provisions of this Agreement and each Warrant referring to the “Company” shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Agreement and each Warrant with the same effect as if such Successor Entity had been
named as the Company herein.

 

    	 	7	 

     

    

  

4.5           Calculations.
All calculations under this Section 4 shall be made to the nearest cent or the nearest
whole share, as the case may be. For purposes of this Section 4, any calculation of the number of Ordinary Shares deemed to
be issued and outstanding as of a given date shall not include treasury shares, if any. In any case in which this Section 4
shall require that an adjustment in the Exercise Price be made effective as of a record date for a specified event, if the
Registered Holder exercises a Warrant after such record date, the Company may elect to defer, until the occurrence of such
event, the issuance of the Ordinary Shares and other share capital of the Company in excess of the Ordinary Shares and other
share capital of the Company, if any, issuable upon such exercise on the basis of the Exercise Price in effect prior to such
adjustment; provided, however, that in such case the Company or the Warrant Agent shall deliver to
the Registered Holder a due bill or other appropriate instrument evidencing the Registered Holder’s right to receive
such additional shares and/or other capital securities upon the occurrence of the event requiring such
adjustment.

 

4.6           Notices
of Changes in Warrant. Upon every adjustment of the Exercise Price or the number of shares issuable upon exercise of a Warrant,
the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from
such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a
Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon
the occurrence of any such adjustment the Company shall give written notice to each Registered Holder, at the last address set
forth for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice,
or any defect therein, shall not affect the legality or validity of such event. 

 

4.7           No
Fractional Shares. Notwithstanding any provision contained in this Warrant Agreement to the contrary, the Company shall not
issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder
of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company
shall, upon such exercise, round up to the nearest whole number the number of the Ordinary Shares to be issued to the Warrant holder.

 

4.8           Form
of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants issued
after such adjustment may state the same Exercise Price and the same number of shares as is stated in the Warrants initially issued
pursuant to this Agreement. However, the Company may, at any time, in its sole discretion, make any change in the form of Warrant
that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned,
whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

 

4.9           Other
Events. In case any event shall occur affecting the Company as to which none of the provisions
of preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms
of the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of
this Section 4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking
or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the
rights represented by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine
that an adjustment is necessary, the terms of such adjustment. The Company shall adjust the terms of the Warrants in a manner that
is consistent with any adjustment recommended in such opinion.

 

    	 	8	 

     

    

  

5.           Transfer
and Exchange of Warrants.

 

5.1           Registration
of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant into the Warrant
Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by
appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants
shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the
Warrant Agent to the Company from time to time upon the Company’s request.

 

5.2           Procedure
for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or
transfer, and, thereupon, the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered
Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that, in the event
a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and shall issue
new Warrants in exchange therefor until the Warrant Agent has received an opinion of counsel for the Company stating that such
transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

 

5.3           Fractional
Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which will result in the
issuance of a warrant certificate for a fraction of a warrant.

 

5.4           Warrant
Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the
terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever
required by the Warrant Agent, will supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

 

6.           Other
Provisions Relating to Rights of Registered Holders of Warrants.

 

6.1           No
Rights as Shareholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the
Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights
to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors
of the Company or any other matter.

 

    	 	9	 

     

    

  

6.2           Lost,
Stolen Mutilated or Destroyed Warrants. If any Warrant is lost, stolen, mutilated or destroyed, the Company and the Warrant
Agent may, on such terms as to indemnity or otherwise as they may in their discretion impose (which terms shall, in the case of
a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor and date as the Warrant so
lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company,
whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

6.3           Reservation
of Ordinary Shares. The Company shall at all times reserve and keep available a number of its authorized but unissued Ordinary
Shares that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.

 

6.4           Registration
of the Ordinary Shares. The Company registered the Warrants and the Ordinary Shares underlying
the Warrants in the Registration Statement. The Company will use its reasonable efforts to maintain the effectiveness of such Registration
Statement and the current status of the Prospectus or to file and maintain the effectiveness of another registration statement
and another current prospectus covering the Ordinary Shares issuable upon exercise of the Warrants at any time that the Warrants
are exercisable.  In addition, the Company agrees to use its reasonable best efforts to register such Ordinary Shares
under the blue sky laws of the states of residence of the exercising Warrant holders to the extent an exemption from such registration
is not available. 

 

7.           Concerning
the Warrant Agent and Other Matters. 

 

7.1           Payment
of Taxes. The Company shall not be required to pay any stamp or other tax or charge required to be paid in connection
with the exercise of Warrants; and the Company shall not be required to issue or deliver any Ordinary  Shares until such tax
or other charge shall have been paid or it has been established to the Company’s and the Warrant Agent’s
satisfaction that no such tax or other charge is due.

 

7.2           Resignation, Consolidation, or Merger of Warrant
Agent.

 

    	 	10	 

     

    

  

7.2.1           Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the
office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint, in writing,
a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of
thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder
of the Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of
any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor
Warrant Agent. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be an entity organized and
existing under the laws of the State of New York, in good standing and have its principal office in the Borough of Manhattan, City
and State of New York, and be authorized under such laws to exercise corporate trust powers and subject to supervision or examination
by federal or state authorities. After appointment, any successor Warrant Agent shall be vested with all the authority, powers,
rights, immunities, duties and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant
Agent hereunder, without any further act or deed; but, if for any reason it becomes necessary or appropriate, the predecessor Warrant
Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all
the authority, powers, and rights of such predecessor Warrant Agent hereunder; and, upon request of any successor Warrant Agent,
the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting
in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties and obligations.

 

7.2.2           Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof
to the predecessor Warrant Agent and the transfer agent for the Ordinary Shares not later than the effective date of any such appointment.

 

7.2.3           Merger
or Consolidation of Warrant Agent. Any entity into which the Warrant Agent may be merged or with which it may be consolidated
or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor
Warrant Agent under this Warrant Agreement without any further act on the part of the Company or the Warrant Agent.

 

7.3           Fees
and Expenses of Warrant Agent.

 

7.3.1           Remuneration.
The Company agrees to pay the Warrant Agent reasonable remuneration for its services as Warrant Agent hereunder as set forth
on Exhibit C hereto and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably
incur in the execution of its duties hereunder.

 

7.3.2           Further
Assurances. The Company agrees to perform, execute, acknowledge and deliver, or cause to be performed, executed, acknowledged
and delivered, all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for
the carrying out or performing of the provisions of this Warrant Agreement.

 

7.4           Liability
of Warrant Agent.

 

7.4.1           Reliance
on Company Statement. Whenever, in the performance of its duties under this Warrant Agreement, the Warrant Agent shall deem
it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action
hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be
conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer or Chairman of
the Board of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken
or suffered in good faith by it pursuant to the provisions of this Warrant Agreement.

 

    	 	11	 

     

    

  

7.4.2           Indemnity.
The Warrant Agent shall be liable hereunder only for its own negligence, willful misconduct or bad faith. The Company agrees to
indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel
fees, for anything done or omitted by the Warrant Agent in the execution of this Warrant Agreement, except as a result of the Warrant
Agent’s negligence, willful misconduct or bad faith.

 

7.4.3           Exclusions.
The Warrant Agent shall have no responsibility with respect to the validity of this Warrant Agreement or with respect to the validity
or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of
any covenant or condition contained in this Warrant Agreement or in any Warrant; nor shall it be responsible to make any adjustments
required under the provisions of Section 4 hereof or responsible for the manner, method or amount of any such adjustment or the
ascertaining of the existence of facts that would require any such adjustment; nor shall it, by any act hereunder, be deemed to
make any representation or warranty as to the authorization or reservation of any Ordinary Shares to be issued pursuant to this
Warrant Agreement or any Warrant or as to whether any Ordinary Shares will when issued be valid and fully paid and nonassessable.

 

7.5           Acceptance
of Agency. The Warrant Agent hereby accepts the agency established by this Warrant Agreement and agrees to perform the same
upon the terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants
exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares
of the Company’s Ordinary Shares through the exercise of Warrants.

 

8.           Miscellaneous
Provisions.

 

8.1          Successors.
All the covenants and provisions of this Warrant Agreement by or for the benefit of the Company or the Warrant Agent shall bind
and inure to the benefit of their respective successors and assigns.

 

8.2          Notices.
Any notice, statement or demand authorized by this Warrant Agreement to be given or made by the Warrant Agent or by the holder
of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service,
addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

BioLight Life Sciences Ltd.

Kiryat Atidim

Building 3, 5th Floor

Tel Aviv 6158101

Israel

Attn: Suzana Nahum-Zilberberg, Chief Executive Officer

 

Any notice, statement or demand authorized
by this Warrant Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be
delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed
in writing by the Warrant Agent with the Company), as follows:

 

    	 	12	 

     

    

  

VStock Transfer, LLC

18 Lafayette Place

Woodmere, NY 11598

Attn: Warrant Department

 

Any notice, sent pursuant to this Warrant
Agreement shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight
courier, on the next business day of the delivery to the courier, and if sent by registered or certified mail on the third day
after registration or certification thereof

 

8.3          Applicable
Law. The validity, interpretation, and performance of this Warrant Agreement and of the Warrants shall be governed in all respects
by the laws of the State of New York, without giving effect to conflict of laws. The Company hereby agrees that any action, proceeding
or claim against it arising out of or relating in any way to this Warrant Agreement shall be brought and enforced in the courts
of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to
such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by
transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the
address set forth in Section 8.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the
Company in any action, proceeding or claim.

 

8.4          Persons
having Rights Under this Agreement. Nothing in this Agreement shall be construed to confer
upon, or give to, any person or corporation other than the parties hereto and the Registered Holders of the Warrants any right,
remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof.
All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive
benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.

 

8.5          Examination
of the Warrant Agreement. A copy of this Warrant Agreement shall be available at all reasonable times at the office of the
Warrant Agent for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit
his, her or its Warrant for inspection.

 

8.6          Counterparts-
Facsimile Signatures. This Warrant Agreement may be executed in any number of counterparts, and each of such counterparts shall,
for all purposes, be deemed to be an original, and all such counterparts shall together constitute one and the same instrument.
Facsimile signatures shall constitute original signatures for all purposes of this Warrant Agreement.

 

    	 	13	 

     

    

  

8.7          Effect
of Headings. The section headings herein are for convenience only and are not part of this Warrant Agreement and shall not
affect the interpretation thereof. 

 

8.8          Amendments.

 

8.8.1           This
Agreement and any Warrant certificate may be amended by the parties hereto by executing a supplemental warrant agreement (a “Supplemental
Agreement”), without the consent of any of the Registered Holders, for the purpose of (i) curing any ambiguity, or curing,
correcting or supplementing any defective provision contained herein, or making any other provisions with respect to matters or
questions arising under this agreement that is not inconsistent with the provisions of this agreement or the Warrant certificates,
(ii) evidencing the succession of another corporation to the Company and the assumption by any such successor of the covenants
of the Company contained in this agreement and the Warrants, (iii) evidencing and providing for the acceptance of appointment by
a successor Warrant Agent with respect to the Warrants, (iv) adding to the covenants of the Company for the benefit of the Registered
Holders or surrendering any right or power conferred upon the Company under this Agreement, or (viii) amending this agreement and
the Warrants in any manner that the Company may deem to be necessary or desirable and that will not adversely affect the interests
of the Registered Holders in any material respect.

 

8.8.2           The
Company and the Warrant Agent may amend this Warrant Agreement and the Warrants by executing a Supplemental Agreement with the
consent of the Registered Holders of not fewer than a majority of the unexercised Warrants affected by such amendment, for the
purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Agreement or of modifying
in any manner the rights of the Registered Holders under this Warrant Agreement; provided, however, that, without the consent of
each of the Registered Holders affected thereby, no such amendment may be made that (i) changes the Warrants so as to reduce the
number of shares purchasable upon exercise of the Warrants or so as to increase the Exercise Price (other than as provided
by Section 4), (ii) shortens the period of time during which the Warrants may be exercised, (iii) otherwise adversely affects the
exercise rights of the Registered Holders in any material respect, or (iv) reduces the number of unexercised Warrants the Registered
Holders of which must consent for amendment of this agreement or the Warrants.

 

8.9          Severability.
This Warrant Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall
not affect the validity or enforceability of this Warrant Agreement or of any other term or provision hereof. Furthermore, in lieu
of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Warrant
Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

    	 	14	 

     

    

  

IN WITNESS WHEREOF,
this Warrant Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	BIOLIGHT LIFE SCIENCES LTD.
	 	 
	 	By: 	 
	 	 	[Name, Title]
	 	 
	 	VSTOCK TRANSFER, LLC
	 	 
	 	By: 	 
	 	 	[Name, Title]

 

    	 	15	 

     

    

  

EXHIBIT A

 

Form of Warrant

 

BIOLIGHT LIFE SCIENCES LTD.

WARRANT CERTIFICATE

NOT EXERCISABLE AFTER __________, _______

 

This certifies that the person whose name
and address appears below, or registered assigns, is the registered owner of the number of Warrants set forth below. Each Warrant
entitles its registered holder to purchase BioLight Life Sciences Ltd., a company incorporated under the laws of the State of Israel
(the “Company”) at any time prior to 5:00 P.M. (New York City time) on ______, _____, at the designated office
of Vstock Transfer LLC, as warrant agent (the “Warrant Agent”) set forth below, one ordinary share, NIS 2.5
per share par value, of the Company (each, a “Share” and collectively, the “Shares”), at
price of US$____ per Share, subject to possible adjustments as provided in the Warrant Agreement (as defined below).

 

This Warrant Certificate, with or without
other Warrant Certificates, upon surrender at the designated office of the Rights Agent, may be exchanged for another Warrant Certificate
or Warrant Certificates evidencing the same number of Warrants as the Warrant Certificate or Warrant Certificates surrendered.

 

The terms and conditions of the Warrants
and the rights and obligations of the holder of this Warrant Certificate are set forth in a Warrant Agreement dated as of ______,
2016 (the “Warrant Agreement”), between the Company and the Warrant Agent. A copy of the Warrant Agreement is
available for inspection during business hours at the office of the Warrant Agent.

 

This Warrant Certificate shall not be valid
or obligatory for any purpose until it shall have been countersigned by an authorized signatory of the Warrant Agent.

 

WITNESS the facsimile signature of  proper
officers of the Company.

 

	 	BIOLIGHT LIFE SCIENCES LTD.
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	By:	 
	 	Name:
	 	Title:

 

	Dated:	 
	Countersigned:	 
	 	 
	VSTOCK TRANSFER, LLC	 
	as Warrant Agent	 
	 	 
	By:	 	 	 
	Name:	 
	Title:	 

 

PLEASE DETACH HERE

——————————————————————————————————————

 

    	 	16	 

     

    

  

Certificate No.:_________ Number of Warrants:__________

 

WARRANT CUSIP NO.: ________

 

BIOLIGHT LIFE SCIENCES LTD.

 

 

	[Name & Address of Holder]	 	VSTOCK TRANSFER, LTD., Warrant Agent
	 	 	 
	 	 	By mail:
	 	 	 
	 	 	By hand or overnight courier: 

 

    	 	17	 

     

    

  

EXHIBIT A

 

Form of Election Notice

 

(To Be Executed Upon Exercise Of Warrants
)

 

The undersigned hereby
irrevocably elects to exercise the right, represented by Warrants evidenced by this Warrant Certificate, to receive                 
Shares and herewith tenders payment for such Ordinary Shares to the order of BioLight Life Sciences Ltd., in the amount of US$
             in accordance with the terms hereof.

 

 

The undersigned requests
that a certificate for such Ordinary Shares be registered in the name of                     ,
whose address is                     
and that such certificate be delivered to                     ,
whose address is                                         .
If the number of Warrants being exercised hereby is less than all the Warrants evidenced by this Warrant Certificate, the undersigned
requests that a new Warrant Certificate representing the remaining unexercised Warrants be registered in the name of                                         ,
whose address is                                         ,
and that such Warrant Certificate be delivered to                whose
address is                                         .

 

	 	 	Signature
	 	 
	Date:	 	 
	 	 
	 	 	 
	 	 	Signature Guaranteed

 

Signatures must be guaranteed by an “eligible
guarantor institution” meeting the requirements of the Warrant Agent, which requirements include membership or participation
in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program”
as may be determined by the Warrant Agent in addition to, or in substitution for, STAMP, all in accordance with the Securities
Exchange Act of 1934, as amended.

 

    	 	18	 

     

    

  

EXHIBIT C

 

Warrant Agent Fees

 

Monthly Maintenance Fee

 

Our monthly maintenance fee is calculated based upon the number
of record shareholders per class or series of Warrants:

 

	o	Monthly Maintenance of 1-99 Registered Holder   $99 per month
	o	Monthly Maintenance of 100-200 Registered Holder     $150 per month
	o	Monthly Maintenance of 200-300 Registered Holder     $299 per month
	o	Monthly Maintenance of 300-500 Registered Holder     $399 per month
	o	Monthly Maintenance of 500+ Registered Holder   $749 per month

 

Service Fees

 

The following are a sample of services provided on a per transaction
fee basis as set forth below:

 

	o	Per Warrant Exercise	$45.00
	o	Issuance Per Warrant	$35.00 
	o	Replacement of Lost or Stolen Warrant	$50.00 (paid by Registered Holder)
	o	Lost Registered Holder search (if needed)	$5.00 per Registered Holder per search
	o	Escheatment (if needed)	$50.00 per Registered Holder

 

Other Costs and Excluded Services

 

The company will be billed separately at
cost for certain out-of-pocket expenses such as postage and courier fees.

 

    	 	19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]